ORICOric Pharmaceuticals, Inc.
14.20USD-3.07%Mkt Cap: 1.47B $P/E: —3d ago
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage produ…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
| Headline | Source | Time |
|---|---|---|
Older | ||
 Is ORIC Pharmaceuticals' (ORIC) Equity-Funded ESOP Masking or Clarifying Its Widening Net Losses? In early August 2026, ORIC Pharmaceuticals reported second-quarter and first-half results showing a wider net loss of US$41.49 million and US$77.26 million respectively, but a narrower basic loss per share from continuing operations compared with a year earlier. Just days before, the company also filed a US$12.41 million shelf registration for 1,100,000 common shares under an ESOP-related offering, highlighting ongoing use of equity-based incentives alongside its loss-making operations. We... | ||